Cargando…

Role of bridging therapy during chimeric antigen receptor T cell therapy

Chimeric antigen receptor (CAR) T‐cell therapy has been approved for use in several relapsed/refractory hematologic malignancies and has significantly improved outcomes for these diseases. A number of different CAR T products are now being used in clinical practice and have demonstrated excellent ou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhaskar, Shakthi T., Dholaria, Bhagirathbhai R., Sengsayadeth, Salyka M., Savani, Bipin N., Oluwole, Olalekan O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175845/ https://www.ncbi.nlm.nih.gov/pubmed/35844303 http://dx.doi.org/10.1002/jha2.335

Ejemplares similares

Chimeric antigen receptor‐T cell therapies: The changing landscape
por: Sengsayadeth, Salyka M., et al.
Publicado: (2021)

Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice
por: Sengsayadeth, Salyka, et al.
Publicado: (2021)

CAR T cell therapy in solid tumors: A review of current clinical trials
por: Patel, Urvi, et al.
Publicado: (2021)

Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia
por: Marvin-Peek, Jennifer, et al.
Publicado: (2022)

Chimeric antigen receptor T‐cell therapy: Challenges and framework of outpatient administration
por: Gatwood, Katie S., et al.
Publicado: (2021)

Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic
por: Bachanova, Veronika, et al.
Publicado: (2020)

Securing the graft during pandemic: are we ready for cryopreservation for all?
por: Dholaria, Bhagirathbhai, et al.
Publicado: (2020)

Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome
por: Bhaskar, Shakthi T., et al.
Publicado: (2022)

New‐onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide
por: Mangan, Brendan L., et al.
Publicado: (2020)

Six Month Freedom from Treatment Failure is an Important Endpoint for Acute Graft-Versus-Host Disease Clinical Trials
por: Sengsayadeth, Salyka, et al.
Publicado: (2013)

Chimeric antigen receptor T-cell therapy
por: Burge, Cale, et al.
Publicado: (2023)

Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy
por: Johnson, P Connor, et al.
Publicado: (2022)

High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy
por: Hu, Jiun-Ruey, et al.
Publicado: (2021)

Intestinal Strongyloides causing peritoneal eosinophilia in peritoneal dialysis
por: Saha, Sharmeela, et al.
Publicado: (2012)

Chimeric Antigen Receptor T Cell Therapy in Hematology
por: Ataca, Pınar, et al.
Publicado: (2015)

Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma
por: Khurana, Arushi, et al.
Publicado: (2022)

Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis
por: Reinhardt, Bryanna, et al.
Publicado: (2023)

Posttransplant maintenance therapy in multiple myeloma: the changing landscape
por: Sengsayadeth, S, et al.
Publicado: (2017)

Chimeric Antigen Receptor Therapy for B-cell Malignancies
por: Porter, David L, et al.
Publicado: (2011)

Chimeric antigen receptor T-cell therapy for solid tumors
por: Newick, Kheng, et al.
Publicado: (2016)

Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
por: Dai, Hanren, et al.
Publicado: (2016)

Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
por: Stoiber, Stefan, et al.
Publicado: (2019)

Chimeric antigen receptor T cell therapy for multiple myeloma
por: Hasegawa, Kana, et al.
Publicado: (2019)

Mechanisms of failure of chimeric antigen receptor T-cell therapy
por: Li, Xiaoqing, et al.
Publicado: (2019)

Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma
por: Hosen, Naoki
Publicado: (2019)

Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer
por: Sur, Daniel, et al.
Publicado: (2020)

Chimeric antigen receptor T cell therapies for multiple myeloma
por: Wu, Chao, et al.
Publicado: (2019)

Strategies to Improve Chimeric Antigen Receptor Therapies for Neuroblastoma
por: Sawaisorn, Piamsiri, et al.
Publicado: (2020)

Cardiovascular disease and chimeric antigen receptor cellular therapy
por: Rao, Anjali, et al.
Publicado: (2022)

Chimeric antigen receptor T-cell therapy for multiple myeloma
por: Wang, Zehua, et al.
Publicado: (2022)

Chimeric antigen receptor T-cell therapy for T-ALL and AML
por: Wei, Wenwen, et al.
Publicado: (2022)

Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy
por: Han, Xiao, et al.
Publicado: (2019)

Adjuvant Scrotal Radiation Therapy As Bridging Therapy to Chimeric Antigen Receptor T-Cell Following Extramedullary Relapse in B-Cell Acute Lymphoblastic Leukemia
por: Ladbury, Colton, et al.
Publicado: (2021)

Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
por: Pang, Yanyu, et al.
Publicado: (2018)

Is Chimeric Antigen Receptor T-cell Therapy the Future of Autoimmunity Management?
por: Tahir, Amber
Publicado: (2018)

Increasing the safety and efficacy of chimeric antigen receptor T cell therapy
por: Li, Hua, et al.
Publicado: (2017)

Switching on the green light for chimeric antigen receptor T‐cell therapy
por: Mardiana, Sherly, et al.
Publicado: (2019)

Biomarkers in individualized management of chimeric antigen receptor T cell therapy
por: Du, Mengyi, et al.
Publicado: (2020)

Cardiovascular Risk Profile of Chimeric Antigen Receptor T-cell Therapy
por: Ahmed, Talha
Publicado: (2020)

Advances Of Chimeric Antigen Receptor T Cell Therapy In Ovarian Cancer
por: Yan, Wenying, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_585emtiqhbfev7ih0hssg0qg7m